Genfit CEO Prigent outlines Iqirvo outlook after Ipsen H1 results

• Genfit management released a Q&A video interview on Aug. 3, 2026, featuring CEO Pascal Prigent.
• Prigent discussed Iqirvo prospects following Ipsen’s first-half 2026 results published on July 30.
• The interview also addressed shareholder questions on elafibranor in PBC and PSC.
• Genfit’s non-invasive diagnostic technology development in MASH was also covered.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.